Calcimedica secures credit facility for up to $32.5 million

$10 million funded at close extends cash runway into mid-2026 la jolla, calif. , march 5, 2025 /prnewswire/ -- calcimedica inc. ("calcimedica" or the "company") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that the company has entered into a credit facility with avenue venture opportunities fund ii, l.p.
CALC Ratings Summary
CALC Quant Ranking